Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,002,177 papers from all fields of science
Search
Sign In
Create Free Account
Antiparkinson Agents
Known as:
antiparkinsonian drugs
, ANTI-PARKINSON DRUGS
, Antiparkinson Drugs
Expand
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
47 relations
Narrower (38)
24 HR Pramipexole dihydrochloride 0.75 MG Extended Release Oral Tablet
24 HR Rotigotine 0.0417 MG/HR Transdermal System
24 HR Rotigotine 0.25 MG/HR Transdermal System
Apomorphine
Expand
Broader (1)
Central Nervous System Depressants
Cholinergic Antagonists
Dopamine Agonists
In Blood
Parasympatholytics
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
J. Beaulieu
,
R. Gainetdinov
Pharmacological Reviews
2011
Corpus ID: 2545878
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic…
Expand
Highly Cited
2010
Highly Cited
2010
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
K. Follett
,
F. Weaver
,
+23 authors
D. Reda
New England Journal of Medicine
2010
Corpus ID: 205091437
BACKGROUND Deep-brain stimulation is the surgical procedure of choice for patients with advanced Parkinson's disease. The globus…
Expand
Highly Cited
2009
Highly Cited
2009
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
S. Leucht
,
C. Corves
,
D. Arbter
,
R. Engel
,
Chunbo Li
,
John M. Davis
The Lancet
2009
Corpus ID: 1071537
Highly Cited
2005
Highly Cited
2005
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.
P. Remy
,
M. Doder
,
A. Lees
,
N. Turjanski
,
D. Brooks
Brain : a journal of neurology
2005
Corpus ID: 4525965
The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration of…
Expand
Highly Cited
2002
Highly Cited
2002
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor…
M. Millan
,
L. Maiofiss
,
D. Cussac
,
V. Audinot
,
J. Boutin
,
A. Newman-Tancredi
Journal of Pharmacology and Experimental…
2002
Corpus ID: 6200455
Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents…
Expand
Highly Cited
2000
Highly Cited
2000
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
G. Fénelon
,
F. Mahieux
,
R. Huon
,
M. Ziégler
Brain : a journal of neurology
2000
Corpus ID: 10881491
Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They…
Expand
Review
1996
Review
1996
Neuropharmacology of timing and time perception.
W. Meck
Brain research. Cognitive brain research
1996
Corpus ID: 7031554
Review
1993
Review
1993
Dopamine receptor pharmacology.
P. Seeman
,
H. V. Van Tol
Current Opinion in Neurology and Neurosurgery
1993
Corpus ID: 28510499
Highly Cited
1989
Highly Cited
1989
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
J. Tetrud
,
J. Langston
Science
1989
Corpus ID: 33537318
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's…
Expand
Review
1961
Review
1961
A survey of drug-induced extrapyramidal reactions.
F. Ayd
JAMA
1961
Corpus ID: 8768642
Among 3,775 patients treated with tranquilizers of the phenothiazine group, 1,472 developed extrapyramidal reactions; 21.2% had…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE